Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
| Revenue (TTM) | $11.56B |
| Gross Profit (TTM) | $3.84B |
| EBITDA | $2.27B |
| Operating Margin | 15.20% |
| Return on Equity | 14.60% |
| Return on Assets | 6.40% |
| Revenue/Share (TTM) | $105.09 |
| Book Value | $68.33 |
| Price-to-Book | 3.45 |
| Price-to-Sales (TTM) | 2.24 |
| EV/Revenue | 2.723 |
| EV/EBITDA | 13.97 |
| Quarterly Earnings Growth (YoY) | 15.00% |
| Quarterly Revenue Growth (YoY) | 10.20% |
| Shares Outstanding | $110.37M |
| Float | $109.81M |
| % Insiders | 0.43% |
| % Institutions | 98.78% |
Volatility is currently contracting
DGX heads into Q3 earnings with expected revenue and EPS growth, fueled by strong clinical demand, advanced diagnostics and operational efficiencies.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Test showed 100% specificity, with no false-positive results in the cohort, at both 3- and 5-year follow-up, and sensitivity of 100% and 83.3%, respectively, for predicting disease recurrence SECAUCUS, N.J., Oct. 1, 2026 /PRNewswire/ -- A new study published in The Journal of Molecular Diagnostics showed that the Haystack MRD® test is highly accurate at detecting residual and recurrent disease, demonstrating clinical performance in specimens from the landmark DYNAMIC colorectal cancer trial series.
DGX's 36.3% YTD rise reflects momentum in advanced diagnostics, channel growth, AI adoption and cost savings.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Quest Diagnostics Incorporated's recurring testing demand provides a foundation for growth through hospital partnerships, dialysis services, and advanced diagnostics. Their dialysis testing and advanced diagnostics add growth opportunities, although their value ultimately depends on execution and reimbursement. So far, DGX's cash flows seem to be benefiting from the acquisition strategy, but if this falters, it may lead to write-downs of its sizable goodwill on the balance sheet.
SECAUCUS, N.J., Sept. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its third quarter 2026 financial results on Thursday, October 22, 2026, before the market opens.
DGX study finds nearly one-third of Lyme-seropositive patients had antibodies to another tick-borne pathogen, highlighting broader testing needs.
Quest Diagnostics gains momentum from customer wins, advanced diagnostics and AI initiatives, while reimbursement uncertainty, costs and debt pose challenges.
Quest Diagnostics NYSE: DGX CEO and President Jim Davis said the diagnostic testing company is exceeding the growth framework it outlined at its prior investor day, driven largely by organic growth, consumer-health demand and partnerships rather than a heavier-than-expected pace of acquisitions.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DGX and any ticker you trade — then tracks every position and per-strategy win rate.
